MX2024010608A - Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados. - Google Patents

Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados.

Info

Publication number
MX2024010608A
MX2024010608A MX2024010608A MX2024010608A MX2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A MX 2024010608 A MX2024010608 A MX 2024010608A
Authority
MX
Mexico
Prior art keywords
disorder
macro
medium
substituted heterocycle
related uses
Prior art date
Application number
MX2024010608A
Other languages
English (en)
Spanish (es)
Inventor
Gregory R Ott
Matthew Spendiff
Karl Gibson
Paul Humphries
Bruce Lefker
Original Assignee
Centessa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals Uk Ltd filed Critical Centessa Pharmaceuticals Uk Ltd
Publication of MX2024010608A publication Critical patent/MX2024010608A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2024010608A 2022-03-01 2023-03-01 Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados. MX2024010608A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263315438P 2022-03-01 2022-03-01
US202363439477P 2023-01-17 2023-01-17
PCT/US2023/014275 WO2023167925A1 (en) 2022-03-01 2023-03-01 Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses

Publications (1)

Publication Number Publication Date
MX2024010608A true MX2024010608A (es) 2024-09-23

Family

ID=85772026

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010608A MX2024010608A (es) 2022-03-01 2023-03-01 Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados.

Country Status (12)

Country Link
US (2) US20250236629A1 (https=)
EP (1) EP4486748A1 (https=)
JP (1) JP2025507852A (https=)
KR (1) KR20240157067A (https=)
CN (1) CN119110802A (https=)
AU (1) AU2023228830A1 (https=)
CA (1) CA3245204A1 (https=)
CL (1) CL2024002576A1 (https=)
IL (1) IL315237A (https=)
MX (1) MX2024010608A (https=)
TW (1) TW202400606A (https=)
WO (1) WO2023167925A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
KR20250155550A (ko) 2023-03-16 2025-10-30 다케다 야쿠힌 고교 가부시키가이샤 매크로시클릭 헤테로시클 화합물 및 이의 용도
US20240425521A1 (en) 2023-06-01 2024-12-26 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20200207734A1 (en) 2017-08-03 2020-07-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
SG11202106791XA (en) 2019-01-31 2021-07-29 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof
FI4065585T3 (fi) * 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
WO2022051583A1 (en) * 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists

Also Published As

Publication number Publication date
CN119110802A (zh) 2024-12-10
US20250289828A1 (en) 2025-09-18
CL2024002576A1 (es) 2025-01-10
TW202400606A (zh) 2024-01-01
US20250236629A1 (en) 2025-07-24
JP2025507852A (ja) 2025-03-21
IL315237A (en) 2024-10-01
EP4486748A1 (en) 2025-01-08
WO2023167925A1 (en) 2023-09-07
CA3245204A1 (en) 2023-09-07
AU2023228830A1 (en) 2024-09-12
KR20240157067A (ko) 2024-10-31

Similar Documents

Publication Publication Date Title
WO2022051596A8 (en) Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
MX2024010608A (es) Derivados heterociclicos medio o macrociclicos sustituidos con bencilo y usos relacionados.
EP3610874A1 (en) Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof
BRPI0417687A (pt) derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
WO2012045883A1 (en) Cyclopropylamine inhibitors of oxidases
TW200606129A (en) Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
NO20051265L (no) Anvendelse av og noen nye imidazopyridiner
KR20170108887A (ko) NamPT 억제용 신규 화합물 및 이를 포함하는 조성물
BR112020010429A2 (pt) uso de agonista de kor em combinação com agonista de mor na preparação de fármaco para tratamento da dor
BR112019016248A2 (pt) piridinas substituídas com hidrocarbilssulfonila e uso das mesmas no tratamento de câncer
BR112019016233A2 (pt) piridinas substituídas com heterociclilsulfonila e uso das mesmas no tratamento de câncer
MX2023006578A (es) Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas.
JP7600131B2 (ja) 神経系疾患の予防または治療用薬学的組成物
AU2011232341A1 (en) Improved stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone
CZ285633B6 (cs) Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek
EP3836912B1 (en) Combinations of substituted benzamides and 5-asa agents
NZ517485A (en) Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia
EP2668159A1 (en) 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
NO20082656L (no) N-sulfamoyl-N'-benzopyranpiperidiner som inhibitorer av karbonsyreanhydraser
EP4061371B1 (en) Masitinib for the treatment of sickle cell disease
KR102954666B1 (ko) 병리학적 염증에 대한 새로운 의학적 치료
CN114874202B (zh) 一种用于治疗阿尔茨海默症的药物及其用途
MX2024013549A (es) Heterociclos novedosos, métodos de preparación y usos de los mismos
BR112022008265A2 (pt) Composições farmacêuticas contendo diácido de oligossacarídeo de alginato
WO2025178571A1 (en) Anti-non-tuberculous mycobacteria inhibitors